(VPHM) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
May 26, 2013
(Stock Blog Hub,
4/27/13)
ViroPharma Incorporated (VPHM) recently announced results from a phase II study of its candidate VP20621 (non-toxigenic Clostridium difficile), which is being developed to...(read more)
(Stock Blog Hub,
8/9/12)
The US Food and Drug Administration (FDA) recently approved ViroPharma Incorporated’s (VPHM) supplement to the Cinryze Biologics License Application (BLA)...(read more)
(Penny Stock DD,
2/28/11)
Sangamo Biosciences, Inc. (NASDAQ:SGMO) surged by 12.29% and closed at $8.50 whereas overall traded volume stood at 1.47 million shares for the day as compare to its...(read more)
ViroPharma (VPHM) Company Overview
There is no analysis for VPHM yet. But you can go to Wikinvest to help create one!
